Opendata, web and dolomites

FERTISSIMO

Oxidative Stress as a biomarker for Embryo Selection in IVF Process

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 FERTISSIMO project word cloud

Explore the words cloud of the FERTISSIMO project. It provides you a very rough idea of what is the project "FERTISSIMO" about.

meet    levels    linked    enabled    validation    chain    thrilled    oxidative    media    approved    competition    proprietary    multiple    carmel    completion    stress    won    fertissimo    model    units    invasive    clinical    2009    proof    generation    merck    pregnancy    june    grant    rates    prestigious    physicians    published    analyzer    innovation    profile    patented    magazines    huge    abstract    market    plan    chf    solution    serono    stable    launch    2014    probability    culture    route    trade    preparing    implantation    practitioner    biomarkers    ip    gfi    commercialization    body    care    sme    ultimate    patients    thermochemiluminescence    supply    reducing    business    series    roadmap    embryo    successfully    diagnostics    stratification    embryos    risk    incidence    biomarker    fluids    deploying    tcl    solid    platform    reproductive    point    examination    ivf    quantitative    strategy    fertility    incubated    sound    economical    births    eureka   

Project "FERTISSIMO" data sheet

The following table provides information about the project.

Coordinator
CARMEL DIAGNOSTICS LTD 

Organization address
address: 9 BARLEV HAIM STREET
city: QIRYAT TIVON
postcode: 3608267
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Israel [IL]
 Project website http://www.carmel-diagnostics.com
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-1-2015
 Funding Scheme SME-1
 Starting year 2016
 Duration (year-month-day) from 2016-03-01   to  2016-08-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    CARMEL DIAGNOSTICS LTD IL (QIRYAT TIVON) coordinator 50˙000.00

Map

 Project objective

Abstract: Carmel Diagnostics, established in 2009, is an SME that has developed clinical applications of its novel, proprietary, patented Thermochemiluminescence technology platform – TCL Analyzer™. Carmel has successfully completed “proof of concept” for its main applications: Embryo Selection in IVF process and Risk Stratification for CHF patients. The results were published in leading magazines. The technology enables assessment of Oxidative Stress in body fluids using it as a biomarker for clinical problems linked to levels of oxidative stress. TCL Analyzer is a stable, robust Point of Care system, now in its third generation. There is a huge need, clinical and economical, for novel biomarkers that will enable the physicians with effective embryo selection. With the goal of identifying embryos of high implantation probability, Carmel’s non-invasive solution will meet this need by providing a quantitative assessment of an embryo’s reproductive potential based on a biomarker - the oxidative profile of the culture media in which the embryo is incubated. This will allow the practitioner to improve pregnancy rates while reducing the incidence of multiple births. The Phase-1 project will be focused on preparing sound business plan, based on solid business model and commercialization strategy and to plan the activities for deploying the solution. This will include market and competition analysis, IP analysis, supply chain examination, risk assessment, and preparing roadmap for the clinical validation, product completion and the best route to bring the system to the market and launch it successfully. In June, 2014 Carmel won a prestigious grant of GFI - Grant for Fertility Innovation (by Merck Serono) that enabled it to build a series of improved, stable TCL Analyzer units to be used in the clinical studies. Eureka approved the project as well. Carmel’s experienced management is thrilled to build FERTISSIMO, the ultimate Embryo selection system based on TCL Analyzer.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "FERTISSIMO" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "FERTISSIMO" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

MISTRAL (2020)

Microbiome-based stratification of individuals at risk of HIV-1 acquisition, chronic clinical complications,antimicrobial drug resistance,and unresponsiveness to therapeutic HIV-1 vaccination

Read More  

FAIR (2020)

FLAGELLIN AEROSOL THERAPY AS AN IMMUNOMODULATORY ADJUNCT TO THE ANTIBIOTIC TREATMENT OF DRUG-RESISTANT BACTERIAL PNEUMONIA

Read More  

TT4CL (2019)

Clinical development of oral oleylphosphocholine as a new drug for the treatment of Old World Cutaneous Leishmaniasis

Read More